GlassScriptPhysician profile
Bradley D Stauber
NPI 1083980643
$17,017.28
in general payments reported to CMS, 2019-2025
42 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $2,222 · 2021: $3,822 · 2022: $3,769 · 2023: $2,189 · 2024: $1,840 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,639.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,791.80 | 2020-2025 | Impella |
| Medtronic, INC. | $2,077.08 | 2021-2025 | Ffrangio, Telescope, Symplicity G3 |
| Boston Scientific Corporation | $1,908.81 | 2019-2025 | Synergy, Opticross, Rotapro |
| Amgen INC. | $1,606.09 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,113.17 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $738.41 | 2019-2023 | Farxiga |
| Chiesi USA, INC. | $618.47 | 2020-2025 | Kengreal, Cleviprex |
| Sanofi-Aventis U.S. LLC | $596.93 | 2019-2022 | |
| Amarin Pharma, INC. | $518.58 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $421.73 | 2019-2023 | Xarelto |
| Shockwave Medical, INC | $419.83 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $405.93 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $402.34 | 2021-2024 | Verquvo |
| Biotronik INC. | $307.40 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Stauber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.